| Nota de fuente |
Long-term follow-up of MCL patients treated with single-agent ibrutinib, 2015---cub. (Michael L. Wang) p. 739 (Michael L. Wang, the University of Texas MD Anderson Cancer Center, Houston, TX)
WWW MD Anderson Cancer Center, 30-5-2016---(Luhua (Michael) Wang, M.D. Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX)
|
